Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX101 in healthy volunteers
NCT07107802Phase 1Completed
- Sponsor
- Aurobac Therapeutics
- Start
- Jul 2025
- Primary completion
- Oct 2025
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ATX101 (4 arms), sponsored by Aurobac Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 7 days. Started Jul 2025; status: completed.
02
Drugs
ATX101
Beyond the preview
Go deeper on NCT07107802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107802.